Oncol Lett 21: Article no. 213, 2021; DOI: 10.3892/ol.2021.12474
Subsequently to the publication of the above article, the authors have realized that, in Fig. 1, the chemical structure of 4’-hydroxychalcone was presented without one of its requisite double bonds.
Figure 1.
Experimental design and general in vivo observations. (A) The chemical structure of 4-HC. (B) Experimental design for the evaluation of the chemopreventive effect of 4-HC in male ApcMin mice. Mice were randomly allocated into groups for oral administration with 10 mg/kg/day 4-HC (n=12) or Veh control (n=11) from 8 to 20 weeks of age. Changes in (C) body weight over time and (D) HBG levels at 20 weeks for ApcMin mice orally treated with 4-HC (n=12) or Veh (n=11). Data are presented as the mean ± SEM. *P<0.05, **P<0.01 vs. Veh. 4-HC, 4’-hydroxychalcone; ApcMin, adenomatous polyposis coli multiple intestinal neoplasia mouse model; HGB, hemoglobin; Veh, vehicle.
A corrected version of Fig. 1, including the correct chemical structure of 4’-hydroxychalcone, is shown below. The authors are grateful to the Editor of Oncology Letters for granting them the opportunity to publish this corrigendum, and regret any inconvenience caused to the readership of the Journal.